Sana Biotechnology’s (SANA) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Sana Biotechnology (NASDAQ:SANA) in a report released on Tuesday,Benzinga reports. The firm currently has a $11.00 price objective on the stock.

Other equities analysts have also recently issued research reports about the company. TD Cowen upgraded Sana Biotechnology from a “hold” rating to a “buy” rating in a report on Wednesday, January 8th. Citizens Jmp upgraded Sana Biotechnology from a “market perform” rating to an “outperform” rating and set a $5.00 target price for the company in a report on Tuesday. Finally, Jefferies Financial Group began coverage on Sana Biotechnology in a report on Friday, March 14th. They set a “buy” rating and a $7.00 target price for the company. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $10.80.

Sana Biotechnology Stock Down 17.7 %

SANA opened at $2.28 on Tuesday. Sana Biotechnology has a 12 month low of $1.52 and a 12 month high of $10.50. The company has a fifty day simple moving average of $3.06 and a 200 day simple moving average of $3.20. The stock has a market cap of $509.05 million, a P/E ratio of -1.63 and a beta of 1.63.

Sana Biotechnology (NASDAQ:SANA) last released its quarterly earnings data on Monday, March 17th. The company reported ($0.23) EPS for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.02. On average, equities research analysts expect that Sana Biotechnology will post -1.16 earnings per share for the current fiscal year.

Insider Transactions at Sana Biotechnology

In other news, insider Fmr Llc sold 290,912 shares of the stock in a transaction dated Wednesday, January 8th. The shares were sold at an average price of $6.49, for a total transaction of $1,888,018.88. Following the completion of the transaction, the insider now directly owns 4,541,511 shares in the company, valued at $29,474,406.39. This represents a 6.02 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Company insiders own 31.10% of the company’s stock.

Hedge Funds Weigh In On Sana Biotechnology

A number of large investors have recently modified their holdings of SANA. Cerity Partners LLC acquired a new position in shares of Sana Biotechnology during the 4th quarter worth about $25,000. Tower Research Capital LLC TRC boosted its stake in shares of Sana Biotechnology by 229.9% during the 4th quarter. Tower Research Capital LLC TRC now owns 15,136 shares of the company’s stock worth $25,000 after buying an additional 10,548 shares during the last quarter. Syon Capital LLC acquired a new stake in Sana Biotechnology in the 4th quarter valued at about $27,000. Wilmington Savings Fund Society FSB acquired a new stake in Sana Biotechnology in the 3rd quarter valued at about $29,000. Finally, Ameriprise Financial Inc. acquired a new stake in Sana Biotechnology in the 4th quarter valued at about $29,000. 88.23% of the stock is currently owned by institutional investors and hedge funds.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.